These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979 [TBL] [Abstract][Full Text] [Related]
5. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. Sasaki M; Sato Y; Nakanuma Y Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197 [TBL] [Abstract][Full Text] [Related]
6. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas. Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma. Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531 [TBL] [Abstract][Full Text] [Related]
8. Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion. Kawano S; Kawada MI; Fukushima S; Arai Y; Shibata T; Miyano SW Anticancer Res; 2024 Jun; 44(6):2393-2406. PubMed ID: 38821585 [TBL] [Abstract][Full Text] [Related]
9. Functions of FGFR2 corrupted by translocations in intrahepatic cholangiocarcinoma. Li F; Peiris MN; Donoghue DJ Cytokine Growth Factor Rev; 2020 Apr; 52():56-67. PubMed ID: 31899106 [TBL] [Abstract][Full Text] [Related]
10. TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. Goyal L; Shi L; Liu LY; Fece de la Cruz F; Lennerz JK; Raghavan S; Leschiner I; Elagina L; Siravegna G; Ng RWS; Vu P; Patra KC; Saha SK; Uppot RN; Arellano R; Reyes S; Sagara T; Otsuki S; Nadres B; Shahzade HA; Dey-Guha I; Fetter IJ; Baiev I; Van Seventer EE; Murphy JE; Ferrone CR; Tanabe KK; Deshpande V; Harding JJ; Yaeger R; Kelley RK; Bardelli A; Iafrate AJ; Hahn WC; Benes CH; Ting DT; Hirai H; Getz G; Juric D; Zhu AX; Corcoran RB; Bardeesy N Cancer Discov; 2019 Aug; 9(8):1064-1079. PubMed ID: 31109923 [TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma. Tsujie M; Iwai T; Kubo S; Ura T; Hatano E; Sakai D; Takeda Y; Kaibori M; Kobayashi T; Katanuma A; Katayose Y; Fukase K Jpn J Clin Oncol; 2021 May; 51(6):911-917. PubMed ID: 33822966 [TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma. Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529 [TBL] [Abstract][Full Text] [Related]
14. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. Sia D; Villanueva A; Friedman SL; Llovet JM Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904 [TBL] [Abstract][Full Text] [Related]
15. Combination therapies for targeting FGFR2 fusions in cholangiocarcinoma. Saborowski A; Vogel A; Segatto O Trends Cancer; 2022 Feb; 8(2):83-86. PubMed ID: 34840108 [TBL] [Abstract][Full Text] [Related]
16. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496 [TBL] [Abstract][Full Text] [Related]
17. Polyclonal Secondary Goyal L; Saha SK; Liu LY; Siravegna G; Leshchiner I; Ahronian LG; Lennerz JK; Vu P; Deshpande V; Kambadakone A; Mussolin B; Reyes S; Henderson L; Sun JE; Van Seventer EE; Gurski JM; Baltschukat S; Schacher-Engstler B; Barys L; Stamm C; Furet P; Ryan DP; Stone JR; Iafrate AJ; Getz G; Porta DG; Tiedt R; Bardelli A; Juric D; Corcoran RB; Bardeesy N; Zhu AX Cancer Discov; 2017 Mar; 7(3):252-263. PubMed ID: 28034880 [TBL] [Abstract][Full Text] [Related]
19. EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma. Wu Q; Zhen Y; Shi L; Vu P; Greninger P; Adil R; Merritt J; Egan R; Wu MJ; Yin X; Ferrone CR; Deshpande V; Baiev I; Pinto CJ; McLoughlin DE; Walmsley CS; Stone JR; Gordan JD; Zhu AX; Juric D; Goyal L; Benes CH; Bardeesy N Cancer Discov; 2022 May; 12(5):1378-1395. PubMed ID: 35420673 [TBL] [Abstract][Full Text] [Related]
20. FGFR Inhibitors: Clinical Activity and Development in the Treatment of Cholangiocarcinoma. King G; Javle M Curr Oncol Rep; 2021 Jul; 23(9):108. PubMed ID: 34269915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]